SE459784B - Stabiliserad torr antitrombinberedning - Google Patents

Stabiliserad torr antitrombinberedning

Info

Publication number
SE459784B
SE459784B SE8101065A SE8101065A SE459784B SE 459784 B SE459784 B SE 459784B SE 8101065 A SE8101065 A SE 8101065A SE 8101065 A SE8101065 A SE 8101065A SE 459784 B SE459784 B SE 459784B
Authority
SE
Sweden
Prior art keywords
antithrombin
iii
preparation
sodium chloride
albumin
Prior art date
Application number
SE8101065A
Other languages
English (en)
Swedish (sv)
Other versions
SE8101065L (sv
Inventor
Y Uemura
M Nagatomo
S Funakoshi
T Suyama
Original Assignee
Green Cross Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp filed Critical Green Cross Corp
Publication of SE8101065L publication Critical patent/SE8101065L/
Publication of SE459784B publication Critical patent/SE459784B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8128—Antithrombin III
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials
    • A61L2103/09—Blood or products thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE8101065A 1978-01-07 1981-02-17 Stabiliserad torr antitrombinberedning SE459784B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP53000714A JPS597693B2 (ja) 1978-01-07 1978-01-07 抗トロンビン製剤及びその製法

Publications (2)

Publication Number Publication Date
SE8101065L SE8101065L (sv) 1981-02-17
SE459784B true SE459784B (sv) 1989-08-07

Family

ID=11481420

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8101065A SE459784B (sv) 1978-01-07 1981-02-17 Stabiliserad torr antitrombinberedning

Country Status (10)

Country Link
US (1) US4340589A (fr)
JP (1) JPS597693B2 (fr)
BE (1) BE877439A (fr)
CA (1) CA1126652A (fr)
CH (1) CH645537A5 (fr)
FR (1) FR2460138A1 (fr)
GB (1) GB2064545B (fr)
NL (1) NL181781C (fr)
SE (1) SE459784B (fr)
WO (1) WO1980002798A1 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
DE3176491D1 (en) * 1980-03-05 1987-11-26 Miles Lab Pasteurized therapeutically active protein compositions
US4363319A (en) * 1980-06-30 1982-12-14 Applied Medical Devices, Inc. Ready-to-use bandage incorporating a coagulant composition and method of preparing same
DE3170001D1 (en) * 1980-09-30 1985-05-23 Bayer Ag Method for the production of an antithrombin-heparin complex and pharmaceutical compositions containing the complex
DE3038163A1 (de) * 1980-10-09 1982-05-06 Boehringer Mannheim Gmbh, 6800 Mannheim Thrombininhibitor, seine herstellung und verwendung
JPS5967228A (ja) * 1982-10-07 1984-04-16 Green Cross Corp:The 寒冷不溶性グロブリンの凍結乾燥方法
JPS6054287B2 (ja) * 1983-10-19 1985-11-29 株式会社ミドリ十字 血漿蛋白の加熱処理方法
US4656254A (en) * 1985-12-02 1987-04-07 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor and antithrombin III
DE3624453A1 (de) * 1986-07-19 1988-01-28 Behringwerke Ag Verfahren zur herstellung von humanem antithrombin iii (atiii), dafuer geeignete vektoren und wirtszellen, so erhaltenes, biologisch aktives atiii und dieses enthaltende arzneimittel
DE3625090A1 (de) * 1986-07-24 1988-01-28 Behringwerke Ag Mittel zur therapie faktor viii-resistenter haemophilie a und verfahren zu seiner herstellung
US4894444A (en) * 1987-07-16 1990-01-16 Merck & Co., Inc. Recovery and purification of immunogens from immunogen-alum complexes
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
CA1331133C (fr) * 1988-03-01 1994-08-02 Michael Jon Pikal Formulations pharmaceutiques d'hormone de croissance humaine
CA1341379C (fr) 1988-04-28 2002-07-23 Welfide Corporation Antithrombine iii purifiee et leur methode de preparation
JPH03504499A (ja) * 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
JPH03504605A (ja) * 1988-05-27 1991-10-09 セントカー・インコーポレーテツド 抗体産生物の凍結乾燥した配合物
CA1336396C (fr) * 1988-07-25 1995-07-25 Kiyoshi Kita Anticoagulant intra-oculaire renfermant de l'antithrombine iii et methode d'administration
US5252557A (en) * 1988-07-25 1993-10-12 Kiyoshi Kita Administration method of antithrombin
JPH0341033A (ja) * 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
US5591431A (en) * 1990-03-09 1997-01-07 G.D. Searle & Co. Enhancement of clot lysis
AT402367B (de) * 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
JP3494667B2 (ja) * 1992-10-02 2004-02-09 アベンティス ファーマ株式会社 アンチトロンビンｉｉｉ製剤
EP0653212A4 (fr) * 1993-04-05 1997-08-20 Green Cross Corp Preparation liquide d'antithrombine iii et procede pour sa stabilisation.
JP3711561B2 (ja) * 1993-04-05 2005-11-02 三菱ウェルファーマ株式会社 アンチトロンビン−▲ｉｉｉ▼液状製剤およびその安定化方法
US5397479A (en) * 1993-04-26 1995-03-14 International Remote Imaging Systems, Inc. Composition and method for enrichment of white blood cells from whole human blood
US6562781B1 (en) 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
US6491965B1 (en) * 1995-11-30 2002-12-10 Hamilton Civic Hospitals Research Development, Inc. Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
EP0844254A3 (fr) * 1996-11-20 1999-05-12 The Green Cross Corporation Procédé de production de l'antithrombine-III, son procédé de purification, et préparation la contenant
DE19856443A1 (de) 1998-12-08 2000-06-21 Centeon Pharma Gmbh Stabilisiertes Antithrombin III-Präparat
US6518406B1 (en) 1999-06-23 2003-02-11 Octapharma Ag Method for purification of proteins
SE9902388D0 (sv) * 1999-06-23 1999-06-23 Pharmacia & Upjohn Ab Method for purification of proteins
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US20020127698A1 (en) * 2001-01-26 2002-09-12 Ralf Geiben Lynn Serpin drugs for treatment of HIV infection and method of use thereof
US8563693B2 (en) * 2001-01-26 2013-10-22 Acceleration Biopharmaceuticals, Inc. Method of treating human immunodeficiency virus infection in a mammal comprising administering heparin-activated antithrombin III
MXPA04002446A (es) 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
US7498130B2 (en) 2003-05-13 2009-03-03 Massachusetts General Hospital Method of reducing viral load
US20040229778A1 (en) * 2003-05-13 2004-11-18 Elmaleh David R. Pharmaceutical compositions of antithrombin III for the treatment of retroviral diseases
ES2221817B1 (es) * 2004-07-26 2005-10-01 Probitas Pharma, S.A. "soluciones de albumina humana terapeutica con baja actividad del activador de precalicreina (pka) y procedimiento de obtencion de las mismas".
JP2008543842A (ja) * 2005-06-14 2008-12-04 バクスター インターナショナル インコーポレイテッド 薬物−薬物相互作用を最小にするための薬学的処方物
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
EP2236520A1 (fr) * 2009-03-31 2010-10-06 Leukocare Ag Composition de stabilisation pour biomolécules immobilisées
CN102655876B (zh) 2009-11-03 2015-07-15 基立福疗法公司 α-1蛋白酶抑制剂组合物、方法和试剂盒
BR112012012460B1 (pt) 2009-11-24 2020-06-23 Grifols Therapeutics Inc. Método de liofilização de uma composição
EP2834635A4 (fr) 2012-04-03 2015-09-02 Smiths Medical Asd Inc Compositions d'agents de charge d'héparine et procédés associés
CN102973526B (zh) * 2012-12-28 2015-09-09 贵州泰邦生物制品有限公司 人抗凝血酶制剂冷冻干燥过程中的保护剂
CN103041380B (zh) * 2012-12-28 2014-08-06 中国医学科学院输血研究所 人抗凝血酶制剂干热处理过程中的稳定剂
WO2018112780A1 (fr) * 2016-12-21 2018-06-28 Chung Chin Sun Nouveau procédé de conservation de l'activité des protéines du plasma sanguin
CN111537326B (zh) * 2020-05-07 2023-05-16 天津德祥生物技术股份有限公司 制备冻干血小板的方法及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA958339A (en) * 1970-09-19 1974-11-26 Yoshio Yoshimura Stabilization of microorganism cells lytic enzyme
SE392038B (sv) * 1971-09-08 1977-03-14 Kabi Ab Forfarande for isolering av antitrombin ur blod eller blodprodukter
JPS5029005B2 (fr) * 1972-05-08 1975-09-19
JPS532931B2 (fr) * 1973-12-05 1978-02-01
US4087415A (en) * 1976-06-09 1978-05-02 William L. Wilson Antithrombin III
JPS6040859B2 (ja) * 1977-07-27 1985-09-12 喜温 三浦 抗血栓性人工医療材料

Also Published As

Publication number Publication date
FR2460138A1 (fr) 1981-01-23
GB2064545B (en) 1983-03-09
CH645537A5 (en) 1984-10-15
NL181781C (nl) 1987-11-02
JPS597693B2 (ja) 1984-02-20
JPS5495715A (en) 1979-07-28
US4340589A (en) 1982-07-20
NL7905220A (nl) 1981-01-06
WO1980002798A1 (fr) 1980-12-24
SE8101065L (sv) 1981-02-17
NL181781B (nl) 1987-06-01
CA1126652A (fr) 1982-06-29
GB2064545A (en) 1981-06-17
FR2460138B1 (fr) 1982-10-08
BE877439A (fr) 1979-11-05

Similar Documents

Publication Publication Date Title
US4340589A (en) Antithrombin preparation and process for the production thereof
US4877866A (en) Method of producing a virus safe, storage-stable, and intravenously tolerable immunoglobulin-G preparation
JP5719266B2 (ja) ウイルス不活性化熱処理へ供するための血漿タンパク質の寒冷沈降物を安定化する方法
EP0278422B1 (fr) Solutions de gamma-globulines injectables
EP0315968A1 (fr) Formulations de protéines recombinantes ou provenant du plasma dans un milieu de basse force ionique
DK156698B (da) Fremgangsmaade til pasteurisering af et materiale indeholdende et termisk foelsomt, terapeutisk aktivtprotein valgt blandt alfa-l-antitrypsin, antithrombin-iii, praekallikrein, antihaemofil faktor (faktorviii) og fibronectin
JPS63243032A (ja) トロンビンの加熱処理方法
EP0144709A2 (fr) Traitement par la chaleur de fractions du plasma
JPS5967228A (ja) 寒冷不溶性グロブリンの凍結乾燥方法
EP0011739B1 (fr) Procédé pour obtenir le facteur XIII de coagulation du sang dérivant du placenta humain
JPH02108624A (ja) 抗ｈｉｖ作用を有するヘパリンフラグメント及びフラクション
KR950010321B1 (ko) 인간 트롬빈 제제의 가열처리방법
AU772669B2 (en) Process for the inactivation of viruses
JP3024073B2 (ja) タンパク質中のウイルスを不活性化する方法
JP2521551B2 (ja) 抗血友病因子の製造方法
IL44881A (en) Preparation of a blood fraction rich in albumin and alpha and beta-globulins
PT1185551E (pt) Método para purificação de proteínas
JPH01305036A (ja) 血漿蛋白成分の加熱処理方法および血漿蛋白成分製剤
JPS6140392B2 (fr)
DK175644B1 (da) Fremgangsmåde til stabilisering af biologiske og farmaceutiske midler under inaktivering af virale og bakterielle kontaminanter
JPS60155120A (ja) 血漿製剤の製法
JP2717638B2 (ja) 人血液凝固第ｉｘ因子含有製剤
JPH024717A (ja) アンチトロンビン−３製剤
JP2678193B2 (ja) ヒト血漿由来血液凝固第ｘ▲ｉｉｉ▼因子の製造方法
Ng et al. Preparation of high purity factor VIII concentrates

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8101065-4

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 8101065-4

Format of ref document f/p: F